5 listed sites: Taiwan (1); United States (4) - 30 Dec `25EI-001 antibody treatment for nonsegmental vitiligo

EI-001 antibody treatment for nonsegmental vitiligo

Official title: A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

Status: Recruiting now

Description:

Elixiron Immunotherapeutics (Hong Kong) Ltd. plans to enroll about 45 participants. EI-001 is an experimental antibody that blocks interferon-gamma, an inflammatory signal involved in melanocyte damage. Researchers hope it will protect pigment-producing cells and support repigmentation. Possible risks include infusion or allergic reactions, headache, and infections; its full safety profile is not yet known. People ages 18 to 65 may qualify. The study is recruiting at 6 listed sites in United States, and Taiwan.

Start date: December 30, 2025

Completion date: September 30, 2027

Organizer: Elixiron Immunotherapeutics (Hong Kong) Ltd.

Contact: Matthew Campos Site Coordinator

Tel.: 714-375-5970

Email: mcampos@marvelclinical.com

Link: https://clinicaltrials.gov/study/NCT07223229

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference EI-001 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...

  • Will it spread?

    Vitiligo is famously unpredictable, but it doesn't move at random. By looking at thousands of cases, researchers have identified specific patterns of how the condition behaves. ...

  • Is it possible to stop the progression of vitiligo?

    While it's not always possible to quickly stop vitiligo progression, there are some treatments that can help slow or halt the spread of the condition in many cases: Corticostero...